Stopping GLP-1 drugs can quickly erase cardiovascular benefits

Study of 333,687 U.S. veterans found stopping GLP-1 drugs (semaglutide/tirzepatide) for as little as six months was associated with loss of cardiovascular benefit and higher risk of major events, with up to a 22% increased risk after two years off. Continuous three-year GLP-1 use yielded an 18% risk reduction (~4 fewer major events per 100 people over 3 years); interruptions reduced benefit (resumers averaged a 12% reduction vs 18% for continuous; 6-month gaps raised risk by ~4–8%; 1- and 2-year discontinuations increased risk by 14% and 22%, respectively). With ~26% of users stopping and ~23% interrupting ≥6 months, implications for investors and payors include prioritizing adherence, addressing cost and side-effect barriers, and the potential impact on long-term demand for GLP-1 therapies.

Analysis

The economics of GLP‑1s are shifting from a one‑time launch boom to a subscription problem: manufacturers must convert initial demand into predictable lifetime revenue or face stop‑start consumption that undermines both clinical claims and pricing power. That dynamic favors firms that can underwrite adherence with copay assistance, hub services, and outcomes contracts; expect incremental SG&A directed to patient support rather than pure R&D or marketing over the next 12–36 months.

Payers and PBMs are the logical second‑order winners because they can extract value by tying coverage to adherence metrics, creating stickier cash flows and negotiating indications/price concessions in exchange for guaranteed persistence. Conversely, retail/clinic models and smaller entrants that rely on episodic scripts or one‑off patient acquisition face higher churn and unit economics pressure unless they bundle long‑term care management.

Principal tail risks are regulatory pricing actions (CMS negotiation or formulary carve‑outs), supply disruptions that force treatment interruptions, and any class‑level safety signals that could prompt rapid de‑adoption; each would compress top‑line visibility and reprice multiples within quarters. Near‑term catalysts to watch are payer policy announcements and Q&A language on adherence programs (next 3–12 months), manufacturing capacity updates (6–18 months), and earnings commentary from the large GLP‑1 manufacturers on patient retention investments (next two reporting cycles).

Key Decisions for Investors

• Long Novo Nordisk (NVO) 12-month call spread: buy 15% OTM calls / sell 40% OTM calls. Rationale: NVO scales global supply, patient support and has the broadest label runway; spread caps regulatory execution risk while targeting ~30–40% upside if continuity and volume realize. Entry: within 30 trading days. Risk: premium loss if payer pressure or safety headlines compress demand.
• Long Eli Lilly (LLY) 9–18 month LEAPS calls (buy 2027 LEAPS or 12–18 month calls). Rationale: liraglutide/tirzepatide franchise exposure plus pipeline optionality and margin tailwinds from higher ASPs; asymmetric upside if persistence programs succeed. Hedge: buy 6–12 month puts at 10% OTM at 20–30% of notional to protect vs rapid policy shock.
• Long a major PBM / managed‑care operator (e.g., CI or CVS) 6–12 month calls. Rationale: PBMs can monetize adherence programs and steer formularies; expect accelerated capture of specialty script economics if payers prioritize persistence. Target return: 1.5–2x vs downside limited to near‑term multiple rerating on political scrutiny.
• Pair trade (defensive hedge): short small consumer/telehealth weight‑loss players (e.g., WW or telehealth platforms) via puts or small outright short and long a specialty pharmacy / retail operator (WBA) to capture script durability and hub services. Rationale: the market will bifurcate between scale operators that monetize chronic care versus episodic players facing high churn. Timeframe: 3–12 months around quarterly results; risk: binary near‑term sentiment swings on new entrants or reimbursement wins.